tiprankstipranks
Advertisement
Advertisement
Septerna to present preclinical characterization of SEP-479
PremiumThe FlySepterna to present preclinical characterization of SEP-479
25d ago
Septerna price target raised to $53 from $47 at Raymond James
Premium
The Fly
Septerna price target raised to $53 from $47 at Raymond James
25d ago
3 Unknown Small-Cap Stocks with ‘Strong Buy’ Ratings and Up to 70% Upside in 2026
Premium
Market News
3 Unknown Small-Cap Stocks with ‘Strong Buy’ Ratings and Up to 70% Upside in 2026
1M ago
Septerna: Advancing GPCR Pipeline and Strategic Partnerships Support Buy Rating and $40 Price Target
PremiumRatingsSepterna: Advancing GPCR Pipeline and Strategic Partnerships Support Buy Rating and $40 Price Target
3M ago
Septerna Begins Phase 1 Trial of Oral SEP-479
Premium
Company Announcements
Septerna Begins Phase 1 Trial of Oral SEP-479
3M ago
Septerna doses first patients in SEP-479 trial
Premium
The Fly
Septerna doses first patients in SEP-479 trial
3M ago
Septerna: Novo-Backed GPCR Platform and Best-in-Class Potential for Oral MRGPRX2 Inhibitor SEP-631 Support Buy Rating
PremiumRatingsSepterna: Novo-Backed GPCR Platform and Best-in-Class Potential for Oral MRGPRX2 Inhibitor SEP-631 Support Buy Rating
4M ago
Septerna reports Q4 EPS (24c), consensus (22c)
Premium
The Fly
Septerna reports Q4 EPS (24c), consensus (22c)
4M ago
Septerna (SEPN): Early Proof-of-Concept for SEP-631 in Mast Cell–Driven Disease Supports Long-Term Growth Potential
Premium
Ratings
Septerna (SEPN): Early Proof-of-Concept for SEP-631 in Mast Cell–Driven Disease Supports Long-Term Growth Potential
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100